Drugmaker stocks rise 5% within 3 months of Makary exit

Makary's tenure was marked by delays and scrutiny in drug approvals. His removal signals potential regulatory easing, which could speed up approvals and boost investor confidence in pharmaceutical companies.

Implied probability (Yes)

60%